Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Silence Therapeutics plc. (7/14/17). "Press Release: Silence CEO, Ali Mortazavi, Appointed Chairman of Ultromics".

Organisations Organisation Silence Therapeutics plc (AIM: SLN)
  Group Silence Therapeutics (Group)
  Organisation 2 Ultromics Ltd.
Products Product image analysis software
  Product 2 RNAi technology
Persons Person Mortazavi, Ali (Silence Therapeutics 201305– CEO before Director of Corporate Strategy joined 2012)
  Person 2 Conway, Simon (FTI Consulting 201412)
     


Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its CEO Ali Mortazavi has been appointed as Non-Executive Chairman of Ultromics with immediate effect. Ultromics is backed by Oxford Sciences Innovation (OSI).

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:
"I am truly excited to be joining the Board of Ultromics. Artificial Intelligence will increasingly begin to play a bigger role in medicine as well as other sectors. Ultromics plans to use the combination of Man plus machine rather than Man vs machine in medical imaging."


Enquiries:

Silence Therapeutics plc
Ali Mortazavi, Chief Executive Officer
David Ellam, Chief Financial Officer
Tel: +44 (0)20 3457 6900

Media Enquiries:
FTI Consulting
Simon Conway/Brett Pollard/Stephanie Cuthbert
Tel: +44 (0) 20 3727 1000


Notes to Editors


About Ultromics

Ultromics is a platform technology that extracts thousands of data points from a single image, then uses machine learning, a form of Artificial Intelligence (AI), to determine which data points are specific to a certain disease. Currently the technology has been applied to echocardiograms to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%. Ultromics is powered by one of the world’s largest commercially consented image databases and the underlying technology was born out of the University of Oxford. Ultromics was formed in May 2017 after receiving funding from Oxford Sciences Innovation. Visit www.ultromics.com for more information.


About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

   
Record changed: 2017-07-20

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Silence Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px